论文部分内容阅读
目的 通过观察应用终末期肝病模型 (MELD)对人工肝治疗终末期肝病预后的预测作用 ,探讨其在临床的应用价值及人工肝支持系统在终末期肝病治疗中的效果。方法 43例患者随机分为治疗组与对照组 ,对其进行MELD评分 ,并对治疗组进行人工肝后评分 ,观察 3个月后的死亡率。结果 治疗组中 4例治疗前MELD评分大于 40分者 ,3个月死亡率为 10 0 %,17例治疗前评分 30～ 40分者 3个月死亡率为 5 3%,对照组中 6例MELD评分大于 40分者 ,3个月死亡率为 10 0 %,16例治疗前评分 30～ 40分者 3个月死亡率为87%,与治疗组相比P <0 .0 5。结论 MELD评分可以引入临床推广应用 ,人工肝治疗MELD评分在 30～ 40分的终末期肝病是安全有效的。
Objective To observe the predictive value of end-stage liver disease model (MELD) on the prognosis of patients with end-stage liver disease treated by artificial liver and to explore its clinical value and the effect of artificial liver support system in the treatment of end-stage liver disease. Methods Forty-three patients were randomly divided into treatment group and control group. MELD score was applied to the treatment group and artificial liver post-treatment score was given to the treatment group. Mortality after 3 months was observed. Results In the treatment group, the MELD score of 4 cases before treatment was more than 40 points, the mortality rate at 3 months was 10%, the 3-month mortality rate of 17 cases before treatment was 30-40 points, and the control group was 6 cases MELD score greater than 40 points, 3-month mortality was 10 0%, 16 cases before treatment score 30-40 points 3-month mortality was 87%, compared with the treatment group P <0. Conclusion MELD score can be introduced into clinical application. Artificial liver is safe and effective in the treatment of end-stage liver disease with MELD score of 30-40.